---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-119905"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2022-11-17T23:59:59+00:00"
generated_at: "2026-06-21T16:48:19.862560+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics shareholders approve reverse stock split at ratio of 1:3 to 1:20

## Summary
- Proposal 1 passed with 36,030,837 votes for, 2,418,669 against, 450,037 abstentions.
- Board can set exact ratio within 1:3 to 1:20 range before February 28, 2023, or abandon split.
- Proposal 2 (adjournment if needed) also approved, 36,441,099 for, 1,892,580 against.
- No broker non-votes on either proposal; all shares voted.

## SEC filing metadata
- accession: 0001104659-22-119905
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2022-11-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465922119905/0001104659-22-119905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465922119905/tm2230787d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-119905
- JSON: https://secwatch.observer/filing/0001104659-22-119905.json
- Plain text: https://secwatch.observer/filing/0001104659-22-119905.txt

## Key facts
- Shareholder Votes
  Aprea Therapeutics, Inc. shareholders approved Approval of adjournment of the Special Meeting to solicit additional proxies if necessary at the 2022-11-16 meeting.
  - Outcome: passed
  - Meeting: 2022-11-16
  source text: Proposal 2: Stockholders approved the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Reverse Stock Split Proposal. Votes For Votes Against Abstentions Broker Non-Votes 36,441,099 1,892,580 565,864 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922119905/0001104659-22-119905-index.htm
- Shareholder Votes
  Aprea Therapeutics, Inc. shareholders approved Approval of reverse stock split at a ratio between 1-for-3 and 1-for-20 inclusive at the 2022-11-16 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2022-11-16
  source text: Proposal 1: Stockholders approved the amendments to the Company’s Certificate of Incorporation, to effect a reverse stock split at a ratio of 1-for-3 and 1-for-20, inclusive, with the exact ratio to be set within that range at the discretion of the Company’s Board of Directors before February 28, 2023 without further approval or authorization of our stockholders and with our Board of Directors able to elect to abandon such proposed amendment and not effect the Reverse Stock Split authorized by stockholders, in its sole discretion. Votes For Votes Against Abstentions Broker Non-Votes 36,030,837 2,418,669 450,037 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922119905/0001104659-22-119905-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.